Molecular Profile Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Profile Name BRAF class 1
Gene Variant Detail

BRAF class 1 (gain of function)

Relevant Treatment Approaches

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT05786924 Phase I BDTX-4933 A Study of BDTX-4933 in Patients With KRAS, BRAF and Select RAS/MAPK Mutation-Positive Cancers Recruiting USA 0
NCT06270082 Phase I IK-595 Study of IK-595 in RAS- or RAF-altered Advanced Tumors Recruiting USA 0
NCT06208124 Phase Ib/II IMM-6-415 A Study of IMM-6-415 in RAS/RAF Mutant Solid Tumors Recruiting USA 0
NCT04916236 Phase I LY3214996 + RMC-4630 Combination Therapy of RMC-4630 and LY3214996 in Metastatic KRAS Mutant Cancers (SHERPA) Recruiting NLD 0
NCT04913285 Phase I Binimetinib + Exarafenib Exarafenib A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors Recruiting USA | NLD | FRA | ESP | AUS 3
NCT05512208 Phase II Defactinib + RO5126766 A Phase 2 Study of Avutometinib (VS-6766) Plus Defactinib (DURAFAK) Recruiting USA 0